[go: up one dir, main page]

AR002757A1 - Oligonucleotidos especificos para virus de hepatitis c, composicion farmaceutica que los contienen, uso de dicho oligonucleotido, un kit para ladeteccion y metodo para dicha deteccion. - Google Patents

Oligonucleotidos especificos para virus de hepatitis c, composicion farmaceutica que los contienen, uso de dicho oligonucleotido, un kit para ladeteccion y metodo para dicha deteccion.

Info

Publication number
AR002757A1
AR002757A1 ARP960102904A AR10290496A AR002757A1 AR 002757 A1 AR002757 A1 AR 002757A1 AR P960102904 A ARP960102904 A AR P960102904A AR 10290496 A AR10290496 A AR 10290496A AR 002757 A1 AR002757 A1 AR 002757A1
Authority
AR
Argentina
Prior art keywords
detection
hepatitis
oligonucleotide
viruses
kit
Prior art date
Application number
ARP960102904A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Hybridon Inc filed Critical Hoffmann La Roche
Publication of AR002757A1 publication Critical patent/AR002757A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención descubre oligonucleótidos sintéticos complementarios a regiones contiguas y no contiguas del RNA de HCV. Se descubren asimismométodos y kits para la inhibición de la replicación de HCV, inhibición de la expresión del ácidon ucleico y proteina de HCV, y para el tratamiento de lasinfecciones de HCV.
ARP960102904A 1995-06-06 1996-06-04 Oligonucleotidos especificos para virus de hepatitis c, composicion farmaceutica que los contienen, uso de dicho oligonucleotido, un kit para ladeteccion y metodo para dicha deteccion. AR002757A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47196895A 1995-06-06 1995-06-06

Publications (1)

Publication Number Publication Date
AR002757A1 true AR002757A1 (es) 1998-04-29

Family

ID=23873702

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960102904A AR002757A1 (es) 1995-06-06 1996-06-04 Oligonucleotidos especificos para virus de hepatitis c, composicion farmaceutica que los contienen, uso de dicho oligonucleotido, un kit para ladeteccion y metodo para dicha deteccion.

Country Status (10)

Country Link
EP (2) EP1331267A3 (es)
AR (1) AR002757A1 (es)
AT (1) ATE240392T1 (es)
AU (1) AU6221996A (es)
CA (1) CA2226438A1 (es)
DE (1) DE69628167D1 (es)
ES (1) ES2196157T3 (es)
PT (1) PT833902E (es)
WO (1) WO1996039500A2 (es)
ZA (1) ZA964446B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002878A3 (en) * 1998-11-19 2003-11-12 Tosoh Corporation Hepatitis C Virus RNA-binding oligo DNA and method preparing it
DE60043759D1 (de) * 1999-12-13 2010-03-11 Bioniche Life Sciences Inc Therapeutisch nützliche synthetische Oligonukleotide
AU2001281812B2 (en) * 2000-06-08 2005-04-07 Valneva Austria Gmbh Immunostimulatory oligodeoxynucleotides
US6586584B2 (en) 2001-01-29 2003-07-01 Becton, Dickinson And Company Sequences and methods for detection of Hepatitis C virus
WO2003018747A2 (en) * 2001-08-22 2003-03-06 Isis Pharmaceuticals, Inc. Molecular interaction sites of hepatitis c virus rna and methods of modulating the same
ES2270656B1 (es) * 2004-03-25 2008-03-16 Consejo Sup. Investig. Cientificas Secuencia de rna, construccion de rna y dna, y composicion farmaceutica inhibidoras de la proliferacion del virus causante de la hepatitis tipo c (vhc), y sus aplicaciones.
FR2884522A1 (fr) * 2005-04-19 2006-10-20 Larissa Balakireva Methode d'inhibition de la traduction et/ou la replication d'une sequence d'arn par multimerisation d'une de ses regions d'arn non codant replie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE202383T1 (de) * 1992-09-10 2001-07-15 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren für die behandlung von mit hepatitis c viren assoziierten krankheiten
AU5141993A (en) * 1992-09-28 1994-04-26 Chiron Corporation Methods and compositions for controlling translation of hcv proteins
JPH10503364A (ja) * 1994-05-10 1998-03-31 ザ ジェネラル ホスピタル コーポレーション Ｃ型肝炎ウイルスのアンチセンス阻害

Also Published As

Publication number Publication date
WO1996039500A3 (en) 1997-03-13
EP1331267A2 (en) 2003-07-30
EP0833902A2 (en) 1998-04-08
EP0833902B1 (en) 2003-05-14
PT833902E (pt) 2003-09-30
CA2226438A1 (en) 1996-12-12
ATE240392T1 (de) 2003-05-15
ES2196157T3 (es) 2003-12-16
EP1331267A3 (en) 2003-12-03
AU6221996A (en) 1996-12-24
ZA964446B (en) 1996-12-06
WO1996039500A2 (en) 1996-12-12
DE69628167D1 (de) 2003-06-18

Similar Documents

Publication Publication Date Title
ES2188760T3 (es) Oligonucleotidos especificos para el virus de la hepatitis b.
BRPI0409068A (pt) composições farmacêuticas para inibidores de protease viral de hepatite c.
CY1107294T1 (el) Τοπικη συνθεση η οποια περιεχει τουλαχιστον μια βιταμινη d ή ενα αναλογο της βιταμινης d και τουλαχιστον ενα κορτικοστεροειδες
AR038568A1 (es) Anticuerpos anti-a beta y su uso
BR0305259A (pt) Inibidores de hcv ns5b polimerase
CO4480111A1 (es) Anticuerpos monoclonales de mono especificos para humanos b7. y/o b7.2, formas primatizadas de los mismos, composicio- nes farmaceuticas que los contienen, y uso de los mismos co- mo inmunosupresantes
CY1110530T1 (el) Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων
ATE112310T1 (de) Hemmung von htlv-iii durch exogene oligonukleotide.
EA199901031A1 (ru) Производные бензимидазола
EA200001133A1 (ru) Антипикорнавирусные композиции, их получение и применение
DK1313462T3 (da) Anvendelse af asiatisk syre eller asiaticosid til behandling af cancer
AR002757A1 (es) Oligonucleotidos especificos para virus de hepatitis c, composicion farmaceutica que los contienen, uso de dicho oligonucleotido, un kit para ladeteccion y metodo para dicha deteccion.
ES2145742T3 (es) Uso de una proteasa de herpes.
TR199900561T2 (xx) G-protein i�levinin engellenmesi i�in ve �o�almaya y�nelik hastal�klar�n iyile�tirilmesi i�in yararl� trisiklik bile�ikler.
AR002758A1 (es) Oligonucleotidos especificos para virus de papiloma humano, composicion farmaceutica que los contiene, el uso de los oligonucleotidos, un kit para ladeteccion y el metodo para dicha deteccion.
BR0315836A (pt) Derivados de [6,7-dihidro-5h-imidazol[1,2-alfa]imadazol-3-sulfonila mino]-propionamida, composição farmacêutica, uso do mesmo, bem como processo para sua preparação
BR9710919A (pt) Proteina purificada sr-p70
DK1075523T3 (da) Strukturelle proteiner hos fiskepankreassygdomsvirus og anvendelser deraf
BR0114977A (pt) segmentos preferidos de proteìna de filamento neural e métodos para uso dos mesmos
DE69225960D1 (de) Monoklonale antikörper gegen mögliche hcv-hüllregionen und methoden diese zu benutzen
ES2182827T3 (es) Gen del virus corona canino y usos del mismo.
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion
ATE346087T1 (de) Hepatitis e-virus aus dem schwein und dessen verwendungen
DE59910146D1 (de) Topisch anwendbares arzneimittel zur behandlung von virusinfektionen
BR9814933A (pt) Composto, composicao farmaceutica e metodo de tratamento de infeccao por hiv.